The clonal evolution during long-term clinical course of multiple myeloma

被引：3

作者：

Mishima, Yuko ^{[1
,2
]}

Mishima, Yuji ^{[2
]}

Shirouchi, Yuko ^{[1
]}

Nishimura, Noriko ^{[1
]}

Yokoyama, Masahiro ^{[1
]}

Okabe, Takashi ^{[1
]}

Inoue, Norihito ^{[1
]}

Uryu, Hideki ^{[1
]}

Fukuta, Takanori ^{[1
]}

Hatake, Kiyohiko ^{[3
]}

Terui, Yasuhito ^{[1
,2
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan

[2] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Clin Res, Tokyo, Japan

[3] Int Univ Hlth & Welf, Mita Hosp, Sch Med, Dept Hematol, Tokyo, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2021年 / 113卷 / 02期

关键词：

Multiple myeloma; Gene mutation; Clonal evolution; Resistance for therapy; Somatic gene mutation analysis; DIS3; MUTATIONS; SPECTRUM; EVENTS; GROWTH;

D O I：

10.1007/s12185-020-02979-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Somatic gene mutations related to acceleration disease and clonal evolution in multiple myeloma strongly influence severe clinical outcomes. In this study, we traced the transition of somatic mutations during the clinical course of myeloma patients over a long-term follow-up period (8.5 year average). Seven myeloma cases treated with immuno-chemotherapy at our institution were analyzed with clinical courses and the results of FISH and G-band analyses. Furthermore, the target sequences in regard to 121 genes, related to driver mutations or acceleration of disease in myeloma, were performed using bone marrow myeloma samples by next-generation sequencing, Ion Proton (TM) System. We detected a relationship between an increase in the dominant mutated gene (e.g.,TP53, DIS3, FAM46C, KDM6B, andEGR1) and poor prognosis. In particular, clonal escalation of theTP53mutation could not be overcome by any treatment. The selection of a combination treatment conducted in conjunction with the monitoring of gene mutations is appropriate for long-term survival. Our data demonstrate that long-term follow-up of somatic gene mutations during the clinical course of myeloma is helpful in the development of an effective treatment strategy.

引用

页码：279 / 284

页数：6

共 19 条

[1] Heterogeneity of genomic evolution and mutational profiles in multiple myeloma [J].

Bolli, Niccolo ;

Avet-Loiseau, Herve ;

Wedge, David C. ;

Van Loo, Peter ;

Alexandrov, Ludmil B. ;

Martincorena, Inigo ;

Dawson, Kevin J. ;

Iorio, Francesco ;

Nik-Zainal, Serena ;

Bignell, Graham R. ;

Hinton, Jonathan W. ;

Li, Yilong ;

Tubio, Jose M. C. ;

McLaren, Stuart ;

Meara, Sarah O' ;

Butler, Adam P. ;

Teague, Jon W. ;

Mudie, Laura ;

Anderson, Elizabeth ;

Rashid, Naim ;

Tai, Yu-Tzu ;

Shammas, Masood A. ;

Sperling, Adam S. ;

Fulciniti, Mariateresa ;

Richardson, Paul G. ;

Parmigiani, Giovanni ;

Magrangeas, Florence ;

Minvielle, Stephane ;

Moreau, Philippe ;

Attal, Michel ;

Facon, Thierry ;

Futreal, P. Andrew ;

Anderson, Kenneth C. ;

Campbell, Peter J. ;

Munshi, Nikhil C. .

NATURE COMMUNICATIONS, 2014, 5

[2] Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents [J].

Chanan-Khan, Asher A. ;

Giralt, Sergio .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2612-2624

[3] Initial genome sequencing and analysis of multiple myeloma [J].

Chapman, Michael A. ;

Lawrence, Michael S. ;

Keats, Jonathan J. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Schinzel, Anna C. ;

Harview, Christina L. ;

Brunet, Jean-Philippe ;

Ahmann, Gregory J. ;

Adli, Mazhar ;

Anderson, Kenneth C. ;

Ardlie, Kristin G. ;

Auclair, Daniel ;

Baker, Angela ;

Bergsagel, P. Leif ;

Bernstein, Bradley E. ;

Drier, Yotam ;

Fonseca, Rafael ;

Gabriel, Stacey B. ;

Hofmeister, Craig C. ;

Jagannath, Sundar ;

Jakubowiak, Andrzej J. ;

Krishnan, Amrita ;

Levy, Joan ;

Liefeld, Ted ;

Lonial, Sagar ;

Mahan, Scott ;

Mfuko, Bunmi ;

Monti, Stefano ;

Perkins, Louise M. ;

Onofrio, Robb ;

Pugh, Trevor J. ;

Rajkumar, S. Vincent ;

Ramos, Alex H. ;

Siegel, David S. ;

Sivachenko, Andrey ;

Stewart, A. Keith ;

Trudel, Suzanne ;

Vij, Ravi ;

Voet, Douglas ;

Winckler, Wendy ;

Zimmerman, Todd ;

Carpten, John ;

Trent, Jeff ;

Hahn, William C. ;

Garraway, Levi A. ;

Meyerson, Matthew ;

Lander, Eric S. ;

Getz, Gad ;

Golub, Todd R. .

NATURE, 2011, 471 (7339) :467-472

[4] Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker [J].

Chavan, S. S. ;

He, J. ;

Tytarenko, R. ;

Deshpande, S. ;

Patel, P. ;

Bailey, M. ;

Stein, C. K. ;

Stephens, O. ;

Weinhold, N. ;

Petty, N. ;

Steward, D. ;

Rasche, L. ;

Bauer, M. ;

Ashby, C. ;

Peterson, E. ;

Ali, S. ;

Ross, J. ;

Miller, V. A. ;

Stephens, P. ;

Thanendrarajan, S. ;

Schinke, C. ;

Zangari, M. ;

van Rhee, F. ;

Barlogie, B. ;

Mughal, T. I. ;

Davies, F. E. ;

Morgan, G. J. ;

Walker, B. A. .

BLOOD CANCER JOURNAL, 2017, 7 :e535-e535

[5] Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma [J].

Chen, Lijuan ;

Wang, Siqing ;

Zhou, Yiming ;

Wu, Xiaosong ;

Entin, Igor ;

Epstein, Joshua ;

Yaccoby, Shmuel ;

Xiong, Wei ;

Barlogie, Bart ;

Shaughnessy, John D. ;

Zhan, Fenghuang .

BLOOD, 2010, 115 (01) :61-70

[6] Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival [J].

Chin, M. ;

Sive, J. I. ;

Allen, C. ;

Roddie, C. ;

Chavda, S. J. ;

Smith, D. ;

Blombery, P. ;

Jones, K. ;

Ryland, G. L. ;

Popat, R. ;

Rismani, A. ;

D'Sa, S. ;

Rabin, N. ;

Gale, R. E. ;

Yong, K. L. .

BLOOD CANCER JOURNAL, 2017, 7 :e610-e610

[7] Multiple myeloma clonal evolution in homogeneously treated patients [J].

Corre, Jill ;

Cleynen, Alice ;

du Pont, Sebastien Robiou ;

Buisson, Laure ;

Bolli, Niccolo ;

Attal, Michel ;

Munshi, Nikhil ;

Avet-Loiseau, Herve .

LEUKEMIA, 2018, 32 (12) :2636-2647

[8] Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma [J].

Dupere-Richer, Daphne ;

Licht, Jonathan D. .

CURRENT OPINION IN HEMATOLOGY, 2017, 24 (04) :336-344

[9] Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides [J].

Egan, Jan B. ;

Shi, Chang-Xin ;

Tembe, Waibhav ;

Christoforides, Alexis ;

Kurdoglu, Ahmet ;

Sinari, Shripad ;

Middha, Sumit ;

Asmann, Yan ;

Schmidt, Jessica ;

Braggio, Esteban ;

Keats, Jonathan J. ;

Fonseca, Rafael ;

Bergsagel, P. Leif ;

Craig, David W. ;

Carpten, John D. ;

Stewart, A. Keith .

BLOOD, 2012, 120 (05) :1060-1066

[10] A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias [J].

Lionetti, Marta ;

Barbieri, Marzia ;

Todoerti, Katia ;

Agnelli, Luca ;

Fabris, Sonia ;

Tonon, Giovanni ;

Segalla, Simona ;

Cifola, Ingrid ;

Pinatel, Eva ;

Tassone, Pierfrancesco ;

Musto, Pellegrino ;

Baldini, Luca ;

Neri, Antonino .

ONCOTARGET, 2015, 6 (28) :26129-26141

← 1 2 →